RYTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rhythm Pharmaceuticals Inc (RYTM) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the recent FDA approval of IMCIVREE for hypothalamic obesity is a positive catalyst, the company's financials still show a net loss, and the technical indicators suggest no clear upward momentum. Additionally, hedge funds are selling, and analysts have lowered their price targets due to recent trial disappointments, signaling caution. With no strong proprietary trading signals and mixed sentiment, holding off on buying is the prudent choice.
The technical indicators are neutral to bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 50.045, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance levels (R2: 97.058) in the pre-market, but there is no clear upward trend.
FDA approval of IMCIVREE for hypothalamic obesity, which is expected to generate significant revenue. Q4 2025 revenue increased by 36.87% YoY, and gross margin improved to 91.61%. Analysts still see long-term growth potential in next-generation candidates and commercial execution.
Phase 3 EMANATE trial failed to meet its primary endpoint, leading to reduced price targets from multiple analysts. Hedge funds are selling heavily, and the stock lacks strong upward momentum in technical indicators. The company is still operating at a net loss, with negative EPS.
In Q4 2025, revenue increased by 36.87% YoY to $57.3 million, but the company reported a net loss of $48.84 million, albeit a 9.42% improvement YoY. EPS improved slightly to -0.73, and gross margin increased to 91.61%.
Analysts maintain a generally positive outlook with Buy and Outperform ratings, but most firms have lowered their price targets due to the EMANATE trial disappointment. The average price target remains above the current price, but sentiment is cautious.
